BioLine RX Ltd (BLRX) CEO Philip Serlin on Q2 2020 Results - Earnings Call Transcript

BioLine RX Ltd (NASDAQ:BLRX) Q2 2020 Earnings Conference Call August 6, 2020 10:00 AM ET

Company Participants

Timothy McCarthy - LifeSci Advisors
Philip Serlin - CEO
Mali Zeevi - CFO
Abi Vainstein - VP, Clinical Development

Conference Call Participants

Joseph Pantginis - H.C. Wainwright & Co.
Mark Breidenbach - Oppenheimer

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2020 Results Conference Call. [Operator Instructions].

I would now like to turn the call over to Timothy McCarthy of LifeSci Advisors to read the safe harbor statement. Tim, please go ahead.

Timothy McCarthy

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results.

These include, but are not limited to, the risk factors and other qualifications contained in BioLineRx' annual report on Form 20-F, quarterly reports filed in the 6-K and other reports filed by BioLineRx with the SEC, to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.

At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.

Philip Serlin

Thank you, Tim, and good morning, everyone. And thank you for joining us on our second quarter earnings conference